China’s National Development and Reform Commission (NDRC) issued a drug price reform policy, which officially withdraws government price setting of all drug products except narcotics and class 1 psychoactives, in an attempt to allow the centralized drug purchase system, basic medical insurance system and market forces to determine actual drug prices from 1st June 2015.
Home > pharmaceuticals
In this article we will look at the basics of the EU VAT Directive, and the going rates in some EU countries for pharmaceutical and medicinal products. Interesting to remember, is that the EU VAT Directive reduces the standardized mandated EU rate for certain branches of the economy, to allow them greater market flexibility and […]
In most regulated economies, thriving sectoral activity of any industry will provide employment. In particular to the pharma industry, it will provide therapeutic solutions. Belgium’s Pact for the Future, which we discussed in a previous blog post, was created with the acknowledgement that the Belgian pharma industry’s value reaches far beyond the immediate healthcare perspective.
The bio-pharmaceutical industry is characterized by massive investments, long and rigorous product development and great financial risk, where statistically only two out of ten drugs will earn back the money invested into their development It is therefore crucial for investors and the pharma industry that the framework they are operating in is hospitable, stable, and […]
The latest official estimation of the value of the Belgian pharma market, published by the Federal Agency for Medicines and Health Products (FAGG or FAMHP) in 2014, discloses the market value of 2012 and provides the net value as 4.49 bln Euro.
There has been a great amount of buzz and positive expectation in relation to Indonesia’s growth potential in the last few years and this is especially true when referring to the healthcare industry. Drivers for growth in the healthcare sector are similar to those identified in many of the original “BRIC” countries and include: A […]
The total healthcare market in Australia accounted for € 88 Bln in 2013 and will continue to grow at 5 percent per year until 2016. The following article summarizes the current situation and forecast of capital equipment, medical instruments, medical devices and pharmaceuticals markets in the country. Further in depth information on Australia’s economic overview and healthcare system is […]
This article gives an overview of the leading market indicators and the key drivers which will shape the Turkish medical technology market in the coming years. It is based on the inputs of policy makers, hospital managers, care providers and the MedTech industry.
Following some of our latest results in emerging markets, the Brazilian healthcare market is still poised for rapid growth from 2011-2015 with a compound annual growth rate of 12.6%. Because of the healthy market, many manufacturers are looking to introduce their new products. Brazil however, offers unique challenges when introducing new products. A good local […]
This year it is more than 30 years ago that US Medicare adopted the system of Diagnosis Related Groups as part of their Prospective Payment System primarily to control the rapid rising costs of healthcare and as an initial effort to retain the solvency of the Nation’s Medicare Hospital Insurance Trust Fund.